Multisubstituted pyrimidines effectively inhibit bacterial growth and biofilm formation of Staphylococcus aureus

被引:0
作者
Riccardo Provenzani
Paola San-Martin-Galindo
Ghada Hassan
Ashenafi Legehar
Aleksi Kallio
Henri Xhaard
Adyary Fallarero
Jari Yli-Kauhaluoma
机构
[1] University of Helsinki,Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy
[2] University of Helsinki,Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Biofilms are multicellular communities of microorganisms that generally attach to surfaces in a self-produced matrix. Unlike planktonic cells, biofilms can withstand conventional antibiotics, causing significant challenges in the healthcare system. Currently, new chemical entities are urgently needed to develop novel anti-biofilm agents. In this study, we designed and synthesized a set of 2,4,5,6-tetrasubstituted pyrimidines and assessed their antibacterial activity against planktonic cells and biofilms formed by Staphylococcus aureus. Compounds 9e, 10d, and 10e displayed potent activity for inhibiting the onset of biofilm formation as well as for killing pre-formed biofilms of S. aureus ATCC 25923 and Newman strains, with half-maximal inhibitory concentration (IC50) values ranging from 11.6 to 62.0 µM. These pyrimidines, at 100 µM, not only decreased the number of viable bacteria within the pre-formed biofilm by 2–3 log10 but also reduced the amount of total biomass by 30–50%. Furthermore, these compounds were effective against planktonic cells with minimum inhibitory concentration (MIC) values lower than 60 µM for both staphylococcal strains. Compound 10d inhibited the growth of S. aureus ATCC 25923 in a concentration-dependent manner and displayed a bactericidal anti-staphylococcal activity. Taken together, our study highlights the value of multisubstituted pyrimidines to develop novel anti-biofilm agents.
引用
收藏
相关论文
共 89 条
[1]  
Ventola CL(2015)The antibiotic resistance crisis: part 1: causes and threats Pharm. Ther. 40 277-283
[2]  
Rossolini GM(2014)Update on the antibiotic resistance crisis Curr. Opin. Pharmacol. 18 56-60
[3]  
Arena F(2008)Medical biofilms Biotechnol. Bioeng. 100 1-18
[4]  
Pecile P(2012)Biofilm infections, their resilience to therapy and innovative treatment strategies J. Intern. Med. 272 541-561
[5]  
Pollini S(2013)Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity Annu. Rev. Med. 64 175-188
[6]  
Bryers JD(2019)Advanced strategies for combating bacterial biofilms J. Cell. Physiol. 234 14689-14708
[7]  
Romling U(2013)Seven ways to preserve the miracle of antibiotics Clin. Infect. Dis. 56 1445-1450
[8]  
Balsalobre C(2004)Antimicrobial drug development—the past, the present, and the future Clin. Microbiol. Infect. 10 23-31
[9]  
Otto M(2007)Novel approaches to developing new antibiotics for bacterial infections Br. J. Pharmacol. 152 1147-1154
[10]  
Sharahi JY(2011)Pharmacological significance of synthetic heterocycles scaffold: a review Adv. Biol. Res. 5 120-144